Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
$2.94
-3.5%
$3.50
$1.96
$4.61
$9.33M0.9117,582 shs3,223 shs
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
$1.06
-0.9%
$0.90
$0.63
$1.78
$39.29M0.37103,759 shs1,737 shs
Tharimmune, Inc. stock logo
THAR
Tharimmune
$4.87
-6.4%
$2.33
$0.95
$9.08
$27.37M1.563.77 million shs611,216 shs
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
$0.73
+3.2%
$0.69
$0.62
$1.70
$38.10M-0.142.00 million shs211,076 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
+1.32%+2.67%-20.10%-17.20%-23.19%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
0.00%+8.30%+21.53%+6.06%-16.67%
Tharimmune, Inc. stock logo
THAR
Tharimmune
-12.61%-14.89%+319.35%+229.93%+91.18%
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
-0.01%0.00%+7.69%+5.12%-18.41%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
3.0702 of 5 stars
3.55.00.00.02.71.70.0
Tharimmune, Inc. stock logo
THAR
Tharimmune
2.9996 of 5 stars
3.83.00.00.02.92.50.0
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
2.8043 of 5 stars
3.71.00.00.03.32.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
0.00
N/AN/AN/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
3.00
Buy$16.001,409.43% Upside
Tharimmune, Inc. stock logo
THAR
Tharimmune
3.50
Strong Buy$17.00249.29% Upside
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
3.33
Buy$3.00312.65% Upside

Current Analyst Ratings Breakdown

Latest CSCI, XLO, ESLA, and THAR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2025
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
8/6/2025
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/6/2025
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$2.00
(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
$9.59M0.97N/AN/A$2.23 per share1.32
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/AN/AN/AN/A($0.16) per shareN/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/AN/AN/AN/A$0.06 per shareN/A
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
$6.34M5.94N/AN/A$0.14 per share5.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
-$15.31M-$6.01N/AN/A-199.55%-149.49%-54.80%11/11/2025 (Estimated)
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/A-$0.26N/AN/AN/A-1,132.38%-358.54%9/26/2025 (Estimated)
Tharimmune, Inc. stock logo
THAR
Tharimmune
-$12.20M-$6.10N/AN/AN/A-1,239.20%-365.06%N/A
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
-$58.24M-$0.76N/AN/AN/A-374.79%-399.15%-58.68%11/6/2025 (Estimated)

Latest CSCI, XLO, ESLA, and THAR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
N/A-$0.85N/A-$0.85N/A$2.75 million
8/14/2025Q2 2025
Tharimmune, Inc. stock logo
THAR
Tharimmune
-$0.58-$0.64-$0.06-$0.64N/AN/A
8/14/2025Q2 2025
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
-$0.08-$0.16-$0.08-$0.16$8.21 million$8.21 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
N/AN/AN/AN/AN/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/AN/AN/AN/AN/A
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/AN/AN/AN/AN/A
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
N/A
2.98
2.65
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/A
0.16
0.16
Tharimmune, Inc. stock logo
THAR
Tharimmune
N/A
1.17
1.17
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
N/A
2.32
2.32

Institutional Ownership

CompanyInstitutional Ownership
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
0.73%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
0.35%
Tharimmune, Inc. stock logo
THAR
Tharimmune
1.16%
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
54.29%

Insider Ownership

CompanyInsider Ownership
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
0.10%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
55.10%
Tharimmune, Inc. stock logo
THAR
Tharimmune
10.01%
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
6.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
COSCIENS Biopharma Inc. stock logo
CSCI
COSCIENS Biopharma
203.18 million3.17 millionN/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/A37.07 million16.64 millionNot Optionable
Tharimmune, Inc. stock logo
THAR
Tharimmune
25.69 million5.12 millionNot Optionable
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
7051.83 million48.56 millionNot Optionable

Recent News About These Companies

Xilio Revenue Jumps 246 Percent in Q2

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
COSCIENS Biopharma stock logo

COSCIENS Biopharma NASDAQ:CSCI

$2.94 -0.11 (-3.45%)
As of 10:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

Estrella Immunopharma stock logo

Estrella Immunopharma NASDAQ:ESLA

$1.06 -0.01 (-0.93%)
As of 10:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Tharimmune stock logo

Tharimmune NASDAQ:THAR

$4.87 -0.33 (-6.40%)
As of 10:48 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Xilio Therapeutics stock logo

Xilio Therapeutics NASDAQ:XLO

$0.73 +0.02 (+3.16%)
As of 10:47 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.